You are viewing an expired study

This study is not currently recruiting Study Participants on If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Pittsburgh, Pennsylvania 15213

  • HIV Infections


The purpose of this study is to compare 2 combination drug therapies in HIV-infected patients who have never received anti-HIV treatment.

Study summary:

In this open-label study antiretroviral-naive patients are randomized to one of two drug regimens: Arm I: 141W94 (amprenavir), 1592U89 (abacavir), and Combivir (3TC/AZT tablet). Arm II: Nelfinavir and Combivir.


Inclusion Criteria Patients must have: - CD4 count > 50. - HIV RNA > 5,000. - No active AIDS (excluding CD4 count < 200). - Ability to comply with dosing schedule and protocol evaluations. Prior Medication: Allowed: - 3TC or any protease inhibitor, if < 1 week of therapy. - Other nucleoside analogs, if < 4 weeks of therapy. Exclusion Criteria Co-existing Condition: Patients with any of the following symptoms or conditions are excluded: - Active AIDS (not including CD4 count < 200). - Malabsorption syndrome affecting drug absorption. Concurrent Medication: Excluded: Enrollment in any other investigational drug protocol. Prior Medication: Excluded: Non-nucleoside reverse transcriptase inhibitors.



Primary Contact:


Backup Contact:


Location Contact:

Pittsburgh, Pennsylvania 15213
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.